Published: Wednesday, August 01, 2012 Last Updated: Wednesday, August 01, 2012
Alnylam Pharmaceutical received milestone payment from GSK as part of their ongoing collaboration to utilize Alnylam’s RNA interference (RNAi) technology to develop GSK’s cell-culture based influenza vaccine.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.